![Peter Pack](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Pack
No open positions remaining
Profile
Peter Pack was the founder of mtm laboratories AG, founded in 1999, and served as Chief Executive Officer in 2008.
Former jobs include Chief Executive Officer & Director at Crescendo Biologics Ltd. from 2015 to 2019, Non-Executive Chairman at Oxford BioDynamics Plc in 2020, Director-Research & Development at MorphoSys AG, Director at Sartorius Polyplus SAS, Managing Director at Polytech Domilens GmbH, and Partner at EMBL Ventures GmbH.
Education history includes an undergraduate degree from the University of Münster in 1990 and a doctorate from Ludwig-Maximilians-Universität München in 1994.
Former positions of Peter Pack
| Companies | Position | End |
|---|---|---|
| OXFORD BIODYNAMICS PLC | Chairman | 2020-12-13 |
Crescendo Biologics Ltd.
 Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in the development of new medicines based on antibody fragment technology | Chief Executive Officer | 2019-04-30 |
mtm laboratories AG
 mtm laboratories AG Medical SpecialtiesHealth Technology Develops and manufactures diagnostic and detection products for cervical cancer | Founder | 2008-11-13 |
EMBL Ventures GmbH
 EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures is a hands-on, long-term manager which invests in disruptive biology and life-science related products and technologies with global potential, including therapeutics, target validation and drug design, technology platforms, medical devices and diagnostics developed at the EMBL, from EMBL alumni and from non-EMBL third parties. The firm seeks to invest in entrepreneurial management teams with: a combination of relevant technical expertise, drive, business sense and a down-to-earth attitude; ownership of a proprietary core or platform technology generating a proprietary position or clear competitive advantage in a defined market sector and a solution for a problem with a significant advantage in a market of substantial size and the chance to achieve a leading, sustainable market position. EMBL Ventures typically acts as the lead or co-lead investor for initial financing and also participates in follow-up financing. They partner with their investee companies, taking a seat on the board of directors. To maximize the intrinsic value of a technology or product, the firm's investment strategy targets one of the main value inflection points, typically the transition from early development or conceptual stage up to proof of concept. | Private Equity Investor | - |
Polyplus-transfection SA
 Polyplus-transfection SA BiotechnologyHealth Technology Provides cell and gene therapy services | Director/Board Member | - |
Training of Peter Pack
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
80
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
MorphoSys AG
 MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology Develops and manufactures diagnostic and detection products for cervical cancer | Health Technology |
EMBL Ventures GmbH
EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures is a hands-on, long-term manager which invests in disruptive biology and life-science related products and technologies with global potential, including therapeutics, target validation and drug design, technology platforms, medical devices and diagnostics developed at the EMBL, from EMBL alumni and from non-EMBL third parties. The firm seeks to invest in entrepreneurial management teams with: a combination of relevant technical expertise, drive, business sense and a down-to-earth attitude; ownership of a proprietary core or platform technology generating a proprietary position or clear competitive advantage in a defined market sector and a solution for a problem with a significant advantage in a market of substantial size and the chance to achieve a leading, sustainable market position. EMBL Ventures typically acts as the lead or co-lead investor for initial financing and also participates in follow-up financing. They partner with their investee companies, taking a seat on the board of directors. To maximize the intrinsic value of a technology or product, the firm's investment strategy targets one of the main value inflection points, typically the transition from early development or conceptual stage up to proof of concept. | Finance |
University of Münster
 University of Münster Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ludwig-Maximilians-Universität München
 Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Polyplus-transfection SA
Polyplus-transfection SA BiotechnologyHealth Technology Provides cell and gene therapy services | Health Technology |
Crescendo Biologics Ltd.
Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in the development of new medicines based on antibody fragment technology | Commercial Services |
Polytech Domilens GmbH
 Polytech Domilens GmbH Electronic ComponentsElectronic Technology Provides research and development services related to ophthalmology | Electronic Technology |
Oxford BioDynamics Plc
 Oxford BioDynamics Plc BiotechnologyHealth Technology Discovers and develops novel biomarkers | Health Technology |
- Stock Market
- Insiders
- Peter Pack
